Friday, June 06, 2025 1:30:58 PM
ABC1212, Andrew Caravello, DO, is really putting out an amazing set of posts. His idea of precision medicine targets as one of the possibilities in the Franchise offering, makes me think of how revolutionary this can be.
Current process:
- surgery lysate to load tumor antigens onto DCs
- highly personalized but requires surgery
Emerging library and tech:
- Dr Ashkan previously said the UK did the whole genome sequencing of 403 glioma tumors, but actually part of of the Genomics England's 100,000 Genomes Project that sequenced 100,000 genomes from "rare conditions or cancer"
- June 2023 Marnix Bosch talked about proteomics on the tumor lysate, "found... 25,000 MHC class 1 associated peptides... almost 13,000 class 2 associated peptides... 400 different tumor-associated peptides... all presented on the dendritic cells... to the immune system"
- Use liquid biopsy (blood draws) to obtain fragments of DNA shed by tumor cells, get biomarkers
What if the NWBO Franchise includes this:
- allogeneic vaccines made from tumor cells of donors (not patients), mass production and storage for off-the-shelf
- that becomes a library or a menu of vaccine components
- for which oncologists or Franchisee members can select antigens
- would then be loaded onto partially matured DCs from a patient’s apheresis
- would create a semi-personalized DCVax-L vaccine
- that is injected into the cancer patient
- and this version still retains all the benefits of the original DCVax-L (ie efficacy, non-toxic, immune memory)
- but this time more quickly, scalable, low cost, and without surgery
Current process:
- surgery lysate to load tumor antigens onto DCs
- highly personalized but requires surgery
Emerging library and tech:
- Dr Ashkan previously said the UK did the whole genome sequencing of 403 glioma tumors, but actually part of of the Genomics England's 100,000 Genomes Project that sequenced 100,000 genomes from "rare conditions or cancer"
- June 2023 Marnix Bosch talked about proteomics on the tumor lysate, "found... 25,000 MHC class 1 associated peptides... almost 13,000 class 2 associated peptides... 400 different tumor-associated peptides... all presented on the dendritic cells... to the immune system"
- Use liquid biopsy (blood draws) to obtain fragments of DNA shed by tumor cells, get biomarkers
What if the NWBO Franchise includes this:
- allogeneic vaccines made from tumor cells of donors (not patients), mass production and storage for off-the-shelf
- that becomes a library or a menu of vaccine components
- for which oncologists or Franchisee members can select antigens
- would then be loaded onto partially matured DCs from a patient’s apheresis
- would create a semi-personalized DCVax-L vaccine
- that is injected into the cancer patient
- and this version still retains all the benefits of the original DCVax-L (ie efficacy, non-toxic, immune memory)
- but this time more quickly, scalable, low cost, and without surgery
Bullish
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
